StockData
Teva Pharmaceutical Industries Ltd logo

Teva Pharmaceutical Industries Ltd

TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30
$41.31−0.19 (-0.46%)

Close on Oct 19, 2026Market cap $48.13BP/E 68.9Yield –

Teva Pharmaceutical Industries GAAP Net Cash Provided by / Operating Activities

GAAP Net Cash Provided by / (Used in) Operating Activities ($M)

Teva Pharmaceutical Industries GAAP Net Cash Provided by / Operating Activities: $241M in Q3 2026, down 34.7% from a year earlier.

Latest, Q3 2026
241
Period ended Sep 30, 2026
Change on a year earlier
-34.7%
369 in Q3 2025
History
43 quarters
Since Q1 2016
Sources
36
Documents cited below

Where the Q3 2026 figure comes from

Source: SEC Form 10-Q (0000818686-26-000006) ↗

Reported in Database (financial_values) & SEC Form 10-Q / 10-K.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedGAAP Net Cash Provided by / (Used in) Operating Activities ($M)Year on yearSource
Q3 2026Sep 30, 2026241-34.7%SEC Form 10-Q (0000818686-26-000006) ↗
Q2 2026Jun 30, 2026411+81.1%SEC Form 10-Q (0001193125-26-323619) ↗
Q1 2026Mar 31, 2026-40-61.9%SEC Form 10-Q (0001193125-26-191513) ↗
Q4 2025Dec 31, 20251,158+101.4%SEC Form 10-K (0001193125-26-034532) ↗
Q3 2025Sep 30, 2025369-46.8%SEC Form 10-Q (0000818686-26-000006) ↗
Q2 2025Jun 30, 2025227+120.4%SEC Form 10-Q (0001193125-26-323619) ↗
Q1 2025Mar 31, 2025-105-15.3%SEC Form 10-Q (0001193125-26-191513) ↗
Q4 2024Dec 31, 2024575-51.4%SEC Form 10-K (0001193125-26-034532) ↗
Q3 2024Sep 30, 2024693+13,760.0%SEC Form 10-Q (0001193125-25-266895) ↗
Q2 2024Jun 30, 2024103-68.2%SEC Form 10-Q (0001193125-25-169296) ↗
Q1 2024Mar 31, 2024-124-14.5%SEC Form 10-Q (0001193125-25-114889) ↗
Q4 2023Dec 31, 20231,184+21.7%SEC Form 10-K (0001193125-26-034532) ↗
Q3 2023Sep 30, 20235-99.1%SEC Form 10-Q (0001193125-24-252039) ↗
Q2 2023Jun 30, 2023324+163.4%SEC Form 10-Q (0001193125-24-189924) ↗
Q1 2023Mar 31, 2023-145+195.9%SEC Form 10-Q (0001193125-24-134200) ↗
Q4 2022Dec 31, 2022973+113.4%SEC Form 10-K (0001193125-25-020826) ↗

Breakdown

What makes up GAAP Net Cash Provided by / Operating Activities

Cite this data

StockData. (2026). Teva Pharmaceutical Industries GAAP Net Cash Provided by / Operating Activities ($M), quarterly Q1 2016–Q3 2026 [Data set]. Compiled from Teva Pharmaceutical Industries SEC filings and investor materials. https://stockdatahq.com/stocks/teva/kpis/db-cf-ocf

See every metric in the Teva Pharmaceutical Industries KPI table. Data updated Nov 10, 2026.

See a number that looks wrong?